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The expression of the Adenovirus serotype 5 (Ad5) E1A oncogene sensitizes tumor cells to 
natural killer (NK) cell–mediated killing and tumor rejection in vivo. These effects are 
dependent on the ability of E1A to bind the transcriptional coadaptor protein p300. To test 
the hypothesis that E1A up-regulates ligands recognized by the NKG2D-activating receptor, 
we stably transfected the highly tumorigenic mouse fibrosarcoma cell line MCA-205 with 
Ad5-E1A or a mutant form of E1A that does not interact with p300 (E1A-
 
 
 
p300). Ad5-E1A, 
but not E1A-
 
 
 
p300, up-regulated the expression of the NKG2D ligand retinoic acid early 
inducible (RAE)-1, but not murine ULBP-like transcript 1, another NKG2D ligand, in four 
independently derived MCA-205 transfectants. The up-regulation of RAE-1 by E1A 
targeted MCA-205 tumor cells to lysis by NK cells, resulting in NKG2D-dependent tumor 
rejection in vivo. Moreover, the up-regulation of NKG2D ligands by E1A was not limited to 
mouse tumor cells, as E1A also increased the expression of NKG2D ligands on primary baby 
mouse kidney cells, human MB435S breast cancer cells, and human H4 fibrosarcoma cells.
 
Adenoviruses (Ads) are ubiquitous human
pathogens that typically cause self-limited viral
infections. In the United States, 95% of adults
are seropositive to one or more of the group C
Ad, such as Ad serotype 2 or serotype 5 (Ad2/5).
Although not known to be oncogenic in
humans, Ad can transform mammalian cells,
including human cells. In Ad-transformed cells,
there is viral integration into the host genome
and the expression of two viral genes (E1A and
E1B) is consistently found. E1A is the primary
immortalizing gene of Ad, and E1B serves as a
“helper” gene to increase the efficiency of
E1A-induced transformation (1 and references
therein).
The E1A oncoprotein from all Ad serotypes
expresses two highly homologous conserved re-
gions, CR1 and CR2, which are essential for
E1A-induced immortalization (1). The con-
served regions of E1A serve as high-affinity
binding sites for cell growth regulatory proteins,
including retinoblastoma (Rb) family members
and the transcriptional coadaptor molecules
p300/CBP (1). (In this paper, we do not distin-
guish between the closely related transcriptional
coadaptor molecules p300 and CBP and refer
to both as p300). Mutations within CR1 or
CR2 that eliminate binding to p300 or pRb
abrogate the capacity of E1A to immortalize
primary cells.
The expression of the Ad2/5-E1A oncogene
sensitizes cells to lysis by NK cells, an activity that
is dependent on the capacity of E1A to bind
p300 (2). This activity of E1A leads to the NK
cell–mediated rejection in vivo of tumor cells
that express E1A (2, 3). Although the ability of
E1A to sensitize cells to NK cells was first de-
scribed nearly two decades ago, the molecular
mechanism remains to be elucidated.
The balance of inhibitory and activating
signals delivered by the target cell to the NK
cells determines the susceptibility of a target
cell to NK cell–mediated lysis. E1A does not
block the capacity of class I MHC molecules
expressed on target cells to inhibit NK cell–
mediated killing (4). Therefore, we hypothe-
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sized that the capacity of E1A to sensitize cells to NK cell lysis
was by the E1A-induced up-regulation of ligands on target
cells that interact with activating NK cell receptors. NKG2D
ligands are an attractive candidate because they are up-regu-
lated by a variety of cellular stresses, including viral infection
(5, 6) or conditions promoting DNA damage (7). Further-
more, the forced expression of NKG2D ligands on tumors
sensitizes these cells to NK cell–mediated lysis in vitro and
NK cell–dependent tumor rejection in vivo (8–10). Here, we
have investigated the effect of E1A on the expression of
NKG2D ligands on mouse and human cell lines and the rec-
ognition of these cells by NK cells in vivo and in vitro.
 
RESULTS
E1A up-regulates NKG2D ligand expression on primary 
mouse cells, mouse tumor cells, and human tumor cells
 
Mouse MCA-205 fibrosarcoma cells and MCA-205 cells sta-
bly transfected with E1A (see Materials and methods) were
screened for expression of mouse NKG2D ligands by flow cy-
tometry using a mouse NKG2D–Ig fusion protein. MCA-205
cells transfected with E1A expressed higher amounts of
NKG2D ligands than parental MCA-205 cells as revealed by
staining with mouse NKG2D–Ig fusion protein (not depicted).
To determine which of the NKG2D ligands were up-regu-
lated by E1A, MCA-205 and MCA-205-E1A cells were
stained with mAbs against retinoic acid early inducible (RAE)-1
and murine ULBP-like transcript 1 (MULT1), another NKG2D
ligand. MCA-205-E1A cells expressed substantially higher
amounts of RAE-1 on the cell surface than parental MCA-205
cells (Fig. 1, A–C). The up-regulation of RAE-1 on MCA-205
cells by E1A was specific for RAE-1 because we detected no
significant expression of MULT1 on the surface of the parental
MCA-205 or MCA-205 E1A cells (not depicted).
The best control to demonstrate that the ability of E1A
to up-regulate NKG2D ligands is E1A-specific is to compare
the effect of wild-type E1A with mutant forms of E1A that
do not sensitize cells to NK cell lysis. Previous studies estab-
lished that the expression of E1A, but not a mutant E1A un-
able to bind cellular p300 (E1A-
 
 
 
p300), rendered tumor
cells more sensitive to NK cell–mediated cytotoxicity (2,
11). Therefore, we determined if MCA-205 cells stably
transfected with E1A-
 
 
 
p300 would up-regulate RAE-1 on
the cell surface (Fig. 1). Four independently derived MCA-
205 cell lines transfected with E1A-
 
 
 
p300 (designated
MCA-205 E1A-
 
 
 
p300-C1, -C2, -C3, and -C4) did not
show enhanced NKG2D ligand expression (Fig. 1 and
Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20050240/DC1). In contrast, increased amounts of
RAE-1 were expressed on four independently derived
MCA-205-E1A transfectants (designated MCA-205-E1A-
C1, -C2, -C3 and -C4; Fig.1 and Fig. S1). The different
MCA-205 E1A or E1A-
 
 
 
p300 transfectants were derived si-
multaneously and maintained in cell culture for an equiva-
lent period of time. Therefore, the up-regulation of RAE-1
on MCA-205-E1A cells was due to the expression of E1A
and not a result of a spontaneous up-regulation of RAE-1
due to prolonged cell culture of the cells. Real-time PCR
demonstrated increased transcription of both RAE-1
 
 
 
 and
RAE-1
 
 
 
 in MCA-205 tumor cells that expressed E1A, but
not E1A-
 
 
 
p300 (Fig. 2).
The ability of E1A to up-regulate NKG2D ligands was
not restricted to the MCA-205 fibrosarcoma cell line. The
expression of NKG2D ligands was also up-regulated on pri-
mary baby mouse kidney (BMK) fibroblast cells derived
from p53
 
 
 
/
 
 
 
 mice that were transformed by E1A (Fig. S1;
reference 12). Furthermore, human MB435S breast cancer
cells and human H4 fibrosarcoma cells stably transfected
with E1A demonstrated increased amounts of NKG2D
ligands on the cell surface (Fig. 1, G–J). Consistent with our
observations on MCA-205 cells, H4 cells expressing E1A-
 
 
 
p300 did not up-regulate NKG2D ligand expression (Fig.
1 K). We observed increased amounts of both the MIC and
ULBP proteins on the surface of these human tumor cell
lines transduced with E1A (not depicted).
In our studies, we used two different mutant forms of
E1A that do not bind p300. H4 cells were transfected with a
mutant form of E1A that changed only one residue (arg to
gly residue no. 2). MCA-205 cells were transfected with an
Figure 1. Expression of NKG2D ligands on the surface of parental 
and E1A-expressing murine (MCA-205) and human (MB435S and 
H4) tumor cells. Expression of RAE-1 on the surface of (A) MCA-205, 
(B and C) MCA-205-E1A, and (D) MCA-205-E1A- -p300 tumor cells or (E) 
MCA-205 and (F) MCA-205-E1A- -p300 cells infected with a retrovirus 
that expresses RAE-1 . Expression of NKG2D ligands on the surface of (G) 
MB435S or (H) MB435S-E1A human breast cancer cells. Expression of 
NKG2D ligands on the surface of (I) H4, (J) H4-E1A, or (K) H4-E1A- p300 
human fibrosarcoma cells. 
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E1A-
 
 
 
p300 mutant that deletes residues 48–60 in conserved
region 1 of E1A. Both of the mutant forms of E1A used do
not interact with p300 and do not abolish the ability of E1A
to bind Rb (13, 14). Consequently, the E2F-Rb–regulated
G1/S checkpoint would be abrogated by both E1A and
E1A-
 
 
 
p300 (13, 14), yet only wild-type E1A affected ex-
pression of the NKG2D ligands.
Taken together, these studies showed that the expression
of E1A increased the expression of NKG2D ligands on the
surface of mouse (MCA-205) and human cancer cells (H4
and MB435S), as well as primary mouse cells (BMK) trans-
formed by E1A. In contrast, the expression E1A-
 
 
 
p300, an
E1A mutant unable to bind p300 but able to bind Rb, failed
to increase NKG2D ligands on either mouse or human cells.
Additional studies will be necessary to define the effects of
E1A on p300 that induce transcription of these different
genes encoding distinct NKG2D ligands in human and mouse
cells.
 
Up-regulation of NKG2D ligands by E1A sensitizes tumors to 
lysis by NK cells
 
The relationship between the amounts of RAE-1 molecules
expressed on the surface of the different MCA-205 cell lines
and their sensitivity to NK cell lysis was examined in two
ways. With the neutralizing anti–mouse NKG2D mAb
CX5, we determined the effect on NK cell–mediated killing
by blocking the interaction of NKG2D on NK cells and
RAE-1 on the MCA-205-E1A cells. We also compared the
NK cell–mediated lysis of MCA-205-E1A cells to MCA-
205 and MCA-205-E1A-
 
 
 
p300 cell lines that were trans-
duced with a retrovirus encoding RAE-1
 
 
 
 (Fig. 3). The
neutralizing anti–mouse NKG2D mAb substantially blocked
the NK cell–mediated killing of the MCA-205-E1A cells.
The inhibition of the NK cell killing was incomplete, as
MCA-205-E1A cells were still more sensitive to NK cell ly-
sis than parental MCA-205 cells (Fig. 3 A). MCA-205 or
MCA-205-E1A-
 
 
 
p300 cells that were transduced with a
retrovirus encoding RAE-1
 
 
 
 and selected to express high
amounts of RAE-1
 
 
 
 were more sensitive than their respec-
tive parental cells lines, but less sensitive to NK cell–medi-
ated lysis than MCA-205-E1A cells (Fig. 3, A and B).
We also evaluated whether the up-regulation of NKG2D
ligands by E1A sensitized human H4 tumor cells to lysis by
human NK cells. A neutralizing anti–human NKG2D
mAb significantly blocked the ability of human NK cells
to lyse H4-E1A tumor cells. Again, blocking the interac-
tion of NKG2D with its ligands did not completely inhibit
the NK cell–mediated killing of H4-E1A cells. In both the
mouse MCA-205 and human H4 tumor cell lines, the ad-
dition of an isotype-matched control antibody had no in-
hibitory effect on the NK cell–mediated killing of the tar-
get cells (not depicted). These data indicated that the
capacity of E1A to sensitize cells to lysis by NK cells was
dependent, in part, on the ability of E1A to up-regulate
NKG2D ligands.
Figure 2. The expression of mRNA for RAE-1  and RAE-1  in 
MCA-205, MCA-205-E1A, and MCA-205- p300 tumor cells as 
determined by real-time PCR. (A) mRNA for RAE-1  and (B) RAE-1  in 
MCA-205, MCA-205-E1A, and MCA-205- p300 tumor cells. mRNA levels 
for RAE-1  and RAE-1  were normalized to hypoxanthine-guanine phos-
phoribosyltransferase transcripts in each cell line, and the fold-induction 
of RAE-1 transcripts are reported compared with the parental MCA-205 
cells (hatched line). The three bars indicated for each cell line represent the 
data obtained in three independent experiments.
Figure 3. The role of NKG2D ligands in the NK cell–mediated lysis 
of mouse and human tumor cells that express E1A. (A) MCA-205-E1A, 
(B) MCA-205-RAE-1  (i.e., MCA-205 cells transduced with RAE-1 ), and 
(C) MCA-205-E1A- p300-RAE-1  (MCA-205-E1A- p300 cells transduced 
with RAE-1 ) were incubated with IL-2–activated mouse NK cells at the 
indicated effector–target cell ratio with control rat IgG1 or the neutralizing 
anti–mouse NKG2D mAb CX5 in standard NK cytolysis assays. (B) Human NK 
cell–mediated cytolysis assays using human H4 or H4-E1A target cells 
with control mouse IgG1 or a neutralizing anti–human NKG2D antibody. 
BL refers to the addition of an antibody that blocks the interaction of 
NKG2D with its ligand. The graphs represent the mean of   SEM of three 
(MCA-205) or four (H4) separate experiments. Data points in which the 
SEM was less than five are not shown on the graphs. 
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Up-regulation of RAE-1 by E1A on MCA-205 cells enhances 
NK cell–mediated tumor rejection
 
We examined whether the up-regulation of RAE-1 by E1A
on MCA-205 cells would lead to a reduction in tumorigenic-
ity by enhancing an NK cell–dependent antitumor response.
To determine the tumorigenicity of the different MCA-205
tumor lines, quantitative tumor induction studies were per-
formed and TPD
 
50
 
 values were calculated. Quantitative tumor
induction studies were performed because they are superior to
single-dose tumor induction studies and allow for quantitation
of intermediate tumorigenic phenotypes (15).
In wild-type C57BL/6 mice, the subcutaneous injection
of MCA-205-E1A cells failed to cause progressive tumors,
even with high doses (10
 
7
 
 tumor cells/animal) of tumor cells.
In contrast, progressive tumors were observed after injection
of 
 
 
 
3,000 MCA-205 or MCA-205-E1A-
 
 
 
p300 cells (Fig. 4
A and not depicted). The stable expression of RAE-1 on
MCA-205 tumor cells by transfection of RAE-1
 
 
 
 also re-
sulted in a 100-fold reduction in tumorigenicity compared
with MCA-205 cells (Fig. 4 A).
To directly evaluate the role of NK cells and NKG2D in
immunity against the MCA-205-E1A tumor, we performed
tumor induction studies using B6-
 
Rag1
 
 
 
/
 
 
 
 mice. Individual
groups of mice were treated with control rat IgG1, the non-
depleting neutralizing anti-NKG2D mAb, CX5 (16), or
PK136, an NK cell–depleting mAb that recognizes the
NK1.1 antigen. Mice were then injected with MCA-205-
E1A tumor cells. Mice treated with control rat IgG1 and
challenged with parental MCA-205 cells served as an addi-
tional control. Depletion of NK cells in the mice treated
with anti-NK1.1 mAb and modulation of NKG2D on NK
cells in mice treated with anti-NKG2D mAb was confirmed
by flow cytometry (not depicted). Depletion of NK cells or
blocking the NKG2D receptor substantially increased the
tumorigenicity of MCA-205-E1A cells (Fig. 4 B). Approxi-
mately 3 
 
 
 
 10
 
6
 
 MCA-205-E1A cells (TPD
 
50 
 
 
 
 6.5) were
required to form progressive tumors in 50% of control, rat
IgG1-treated 
 
Rag1
 
 
 
/
 
 
 
 mice. In contrast, progressive tumors
formed after the injection of roughly 300,000 MCA-205-
E1A tumor cells in mice treated with PK136 or CX5. Thus,
the NK cell–mediated, NKG2D-dependent antitumor re-
sponse was capable of eliminating more than 2 
 
 
 
 10
 
6
 
 MCA-
205 tumor cells expressing E1A.
The reduction in tumorigenicity of MCA-205 cells by
E1A was not entirely NKG2D-dependent. MCA-205 cells
that were transfected with RAE-1
 
 
 
 were more tumorigenic
than the MCA-205 cells expressing E1A. Moreover, MCA-
205-E1A cells were less tumorigenic than parental MCA-
205 cells in 
 
Rag1
 
 
 
/
 
 
 
 mice treated with PK136 or CX5 to
deplete NK cells or block NKG2D function, respectively.
E1A has other activities that likely explain the NKG2D-
independent anti-tumorigenic activity of E1A. The expres-
sion E1A sensitizes cells to lysis by macrophages and im-
mune effector molecules, such as perforin/granzyme, TNF-
 
 
 
,
TRAIL, nitric oxide, and Fas-L (17 and references therein).
 
DISCUSSION
 
Our results demonstrated that the expression of E1A up-reg-
ulated the expression of NKG2D ligands on primary mouse
cells (BMK cells), mouse tumor cells (MCA-205 cells), and
human tumor cells (H4 and MB435S cells). The molecular
events that link the expression of E1A to the up-regulation
of NKG2D ligands were not investigated in this study and
remain unknown. E1A does not alter cellular transcription
by binding DNA in a sequence-specific manner. Rather,
E1A modulates cellular transcription by interacting with and
altering the function of a diverse set of cellular proteins, such
as transcription factors, transcriptional coadaptor molecules,
and tumor suppressor gene products. For example, E1A
binds the tumor suppressor protein pRb, resulting in the re-
lease of the cellular transcription factor E2F, thereby over-
riding the G
 
1
 
/S checkpoint and enhancing cellular prolifera-
tion. The mutant E1A-
 
 
 
p300 binds Rb and does not affect
the ability of E1A to override the G
 
1
 
/S checkpoint (14).
Therefore, our data indicated that the ability of E1A to up-
regulate NKG2D and sensitize cells to lysis by NK cells was
independent of this activity of E1A.
Experiments reported herein are consistent with previous
studies that indicate that E1A-p300 binding is required for
the ability of E1A to sensitize cells to lysis by NK cells (2).
Our data demonstrated that in contrast to wild-type E1A,
the expression of E1A-
 
 
 
p300 did not up-regulate the ex-
pression of NKG2D ligands on mouse MCA-205 or human
H4 cells and did not sensitize MCA-205 or H4 cells to lysis
by NK cells. p300 (and CBP) serve as coadaptor molecules
for numerous cellular transcription factors and have the ca-
pacity to remodel chromatin, activities altered upon interact-
ing with E1A. Several other viral oncoproteins also interact
Figure 4. Role of NKG2D in the NK cell–mediated rejection of 
MCA-205-E1A cells. (A) Wild-type B6 or (B) B6-Rag1 /  mice were injected 
subcutaneously with serial log concentrations of cells and observed 
weekly for tumor development for 12 wk. Depletion of NK cells in vivo was 
performed by using the mAb PK136. The interaction between NKG2D and 
NKG2D ligands was blocked in vivo using the neutralizing anti-NKG2D 
mAb CX5. TPD50 values (log10 of the number of tumor cells required to 
produce tumors in 50% of the mice) were calculated on a weekly basis. 
Cells derived from progressive tumors were tested for E1A or RAE-1 
expression by Western blot analysis and flow cytometry, respectively, to 
confirm expression of E1A and RAE-1 in tumors that emerged to exclude 
transgene loss as a reason for tumor growth. 
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with and alter the function of p300. Therefore, it will be im-
portant to ascertain the molecular mechanism whereby the
interaction of E1A with p300 up-regulates NKG2D ligands
and determine if this mechanism is unique to E1A or a com-
mon pathway used by other viral oncoproteins.
Small DNA tumor viruses, such as Ads, human papillo-
maviruses (HPVs), and polyomaviruses (e.g., SV40), transform
cells from diverse species by using similar molecular mecha-
nisms. The primary immortalizing oncogenes of Ad (E1A),
HPV (E7), and SV40 (large T antigen) contain homologous
conserved regions (CR1 and CR2) that are essential for cel-
lular immortalization and interchangeable in cellular transfor-
mation assays (18). The “helper” oncogenes of Ad (E1B),
HPV (E6), and SV40 (large T antigen), which are necessary
for complete cellular transformation, inhibit the function of
the tumor suppressor gene product p53 (18). Despite substan-
tial progress in defining the molecular mechanisms used by
these viruses to transform mammalian cells, a fundamental
question remains: Why do viruses that appear to transform
cells through analogous molecular mechanisms differ so dra-
matically in their oncogenicity, even in species that serve as
natural hosts for virus infection? For example, HPVs, but not
Ads, are oncogenic in humans, their natural host.
Our observations may shed light on this question and
help explain the lack of oncogenicity of Ads in humans. Ad-
transformed human cells are tumorigenic in immunocom-
promised rodents (19), illustrating the potential oncogenicity
of this common human pathogen. Studies using rodents es-
tablished the importance of the cellular immune response in
regulating the oncogenicity of Ad-transformed cells. Primary
cells transformed by Ad2 or Ad5, which are not oncogenic
in immunocompetent rodents, are tumorigenic in animals
with defective NK cell or T cell responses (20, 21). The ec-
topic expression of NKG2D ligands on tumors has been
shown to target these cells to lysis in vivo by both NK cells
and T cells (9, 10, 22). Therefore, the up-regulation of
NKG2D ligand by E1A during a transforming viral infection
may also lead to the elimination of these transformed cells by
both innate and adaptive immune responses.
Viral oncoproteins derived from different small DNA tu-
mor viruses may vary in their ability to up-regulate ligands,
such as NKG2D ligands, recognized by activating NK cell re-
ceptors on innate effector cells. Virally transformed cells that
do not activate innate immune responses may also fail to elicit
effective adaptive immune responses and evade host cellular
antitumor immunity, thereby enhancing their oncogenicity.
This hypothesis is consistent with the inability of E7 to sensi-
tize cells to lysis by NK cells or macrophages and the high
oncogenicity of HPV in humans (3). This hypothesis is also
consistent with the well-described inverse relationship be-
tween the sensitivity of cells transformed by several small
DNA tumor viruses to lysis by NK cells in vitro and the on-
cogenicity of these virus-transformed cells in vivo (23).
In summary, E1A, but not E1A-
 
 
 
p300, up-regulated the
expression of the NKG2D ligands on mouse MCA-205 tu-
mor cells as well as human breast cancer and fibrosarcoma
cells. To our knowledge, E1A is the first example of a vi-
ral oncoprotein that can up-regulate NKG2D ligands and
thereby enhance NK cell–mediated tumor rejection.
 
MATERIALS AND METHODS
 
Plasmids and retroviruses.
 
The pLSXN-E1A and pLSXN-E1A-
 
 
 
p300
retroviruses express wild-type Ad5 E1A and Ad5 E1A-
 
 
 
p300, respectively.
The E1A-
 
 
 
p300 (dl1104) mutant has a deletion in amino acids 48–60 in
CR1, which abrogates binding to p300. Retroviruses containing a RAE-1
 
 
 
cDNA were generated by using the pMx-puro vector (24).
 
Antibodies and NKG2D fusion proteins.
 
CX5 is a neutralizing, non-
depleting rat IgG1 mAb directed against mouse NKG2D that blocks the
binding of NKG2D to its ligands and modulates expression of NKG2D
from the cell surface (25). mAb 186107 (rat IgG2b) binds to RAE-1
 
 
 
,
RAE-1
 
 
 
, RAE-1
 
 
 
, RAE-1
 
 
 
, and RAE-1
 
 
 
 (5), mAb 237104 (rat IgG2a)
recognizes MULT1 (26), and mAb 149810 (mouse IgG1) binds the human
NKG2D receptor and blocks the interaction of the NKG2D receptor with
NKG2D ligands on human cells (27). PK136 is an NK cell–depleting
mouse IgG2a mAb that recognizes NK1.1 (28). Mouse NKG2D–Ig fusion
protein is composed of the extracellular domain of mouse NKG2D and the
Fc fragment of human IgG1 (8).
 
Cell lines.
 
The C57BL/6-derived MCA-205 fibrosarcoma cell line was
provided by N. Restifo (National Cancer Institute, National Institutes of
Health, Bethesda, MD). p53
 
 
 
/
 
 
 
 BMK cells transformed by E1A (12) were
provided by E. White (Rutgers University, Piscataway, NJ). Stable cell lines
were generated by a single transfection of the MCA-205 cell line with
pLSXN-E1A or pLSXN-E1A-
 
 
 
p300 by using the Superfect transfection
reagent (QIAGEN). After transfection, the cells were plated into six-well
plates followed by selection in 1 mg/ml G418 (Sigma-Aldrich). Geneticin-
resistant colonies from separate wells were expanded and screened for ex-
pression of E1A or E1A-
 
 
 
p300 by Western blot analysis (3). MCA-205-
E1A and MCA-205-E1A-
 
 
 
p300 cell lines that expressed high levels of E1A
or E1A-
 
 
 
p300 proteins were subsequently analyzed for NKG2D ligand ex-
pression by using mouse NKG2D–Ig fusion protein. MCA-205 and MCA-
205-E1A-
 
 
 
p300 cell lines were infected with retroviruses containing RAE-
1
 
 
 
 cDNA. After selection in medium containing 1 
 
 
 
g/ml puromycin,
transduced cells stably expressing RAE-1
 
 
 
 were isolated by flow cytometry.
H4, a human fibrosarcoma cell line, and H4-E1A, an Ad5 E1A-transfected
H4 cell line (29 and references therein), were provided by S. Frisch (La Jolla
Cancer Research Institute, La Jolla, CA). H4-E1A-
 
 
 
p300 is an H4 cell line
that expresses a mutant form of E1A unable to bind p300 (29). MB435S, a
human breast cancer line, and MB435S-E1A, an Ad5 E1A-transfected
MB435S cell line, were provided by J. Cook (University of Illinois, Chi-
cago, IL). All cell lines were maintained in DMEM supplemented with 5%
fetal calf serum, 15 mM glucose, and antibiotics.
 
NK cell cytolysis assays.
 
Purified populations of polyclonal mouse NK
cells or human NK cells were used as effectors in a standard 4-h 
 
51
 
Cr-release
cytotoxicity assay, as previously described (8). Human NK cells were iso-
lated from PBMCs by negative selection using the RosetteSep enrichment
cocktail (Stem Cell Technologies, Vancouver, BC) according to the manu-
facturer’s instructions. Polyclonal mouse and human NK cell cultures con-
tained 
 
 
 
90% NK cells as determined by flow cytometry.
 
Tumor induction studies.
 
Quantitative tumor induction studies were
performed as described previously (2). Mice (two [B6 
 
Rag1
 
 
 
/
 
 
 
] or three [B6
mice] animals per cell line at each dose) were injected subcutaneously with
serial log concentrations of cells and observed weekly for tumor development
for 12 wk. Animals were killed when tumors reached 20 mm mean diameter
or at the end of the 12-wk observation period. Tumor induction experiments
were repeated twice in B6 mice. Tumor cells from animals injected with 
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MCA-102-E1A were tested for E1A or RAE-1 expression. TPD
 
50
 
 values,
the log10 of the number of tumor cells required to produce tumors in 50% of
the mice, were calculated as described previously (2). Experiments involving
mice were conducted using protocols approved by the National Jewish Med-
ical and Research Center Animal Care and Use Committee and the Univer-
sity of California, San Francisco, Committee on Animal Research.
Real-time PCR. The expression of mRNA for RAE-1  and RAE-1 
in MCA-205, MCA-205-E1A, and MCA-205- p300 was determined by
real-time PCR. Real-time PCR, including probe sets for RAE-1 , RAE-
1 , and hypoxanthine-guanine phosphoribosyltransferase, were performed
using an ABI 7700 with Sequence Detector Software (Applied Biosystems),
and the conditions were described previously (25, 30).
Online supplemental material. Fig. S1 shows the amounts of RAE-1
expressed on two additional, independently derived MCA-205-E1A and
MCA-205-E1A- p300 cell lines and the expression of NKG2D ligands on
primary and E1A-transformed BMK cells derived from p53 /  mice. Fig. S1
is available at http://www.jem.org/cgi/content/full/jem.20050240/DC1.
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